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Osteoarthritis (OA) is a complex multifactorial disease with a strong genetic component. Several studies
have suggested or identiﬁed epigenetic events that may play a role in OA progression and the gene
expression changes observed in diseased cartilage. The aim of this review is to inform about current
research in epigenetics and epigenetics in OA. Epigenetic mechanisms include DNA methylation, histone
modiﬁcations, and microRNAs. Collectively, these enable the cell to respond quickly to environmental
changes and can be inherited during cell division. However, aberrant epigenetic modiﬁcations are
associated with a number of pathological conditions, including OA. Advancements in epigenetic research
suggests that global analysis of such modiﬁcations in OA are now possible, however, with the exception
of microRNAs, it will be a signiﬁcant challenge to demonstrate how such events impact on the disease.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common degenerative joint
disease and although often accompanied with new bone formation,
changes in the subchondral bone and low-grade synovitis, it is
epitomised by focal degradation of articular cartilage1. The main
risk factor for OA is age and chondrocytes, the sole cell-type in
cartilage, are unusual in that they are effectively post-mitotic after
puberty and must survive and function throughout life2. In health,
chondrocytes respond to their environment to regulate the artic-
ular cartilage by balancing the synthesis of extracellular matrix
(ECM) components, mainly type-II collagen and the proteoglycan
aggrecan, with its turnover and degradation by proteolytic
enzymes, including matrix metalloproteinases (MMP13 being the
major collagenase in OA) and the ‘a disintegrin and metal-
loproteinase domain with thrombospondin-like motifs’ family
(ADAMTS), including the aggrecanases, ADAMTS4 and ADAMTS5.
Prevention of either aggrecan or collagen degradation reduces
cartilage loss in murine arthritis models3. Although broad-
spectrum metalloproteinase inhibitors have not been beneﬁcial in
arthritis partly due to non-selectivity4, the suggestion of targeting
the expression/activity of speciﬁc proteases via uniquemechanismsD.A. Young, Musculoskeletal
or Cookson Building, Medical
HH,UK. Tel: 44-191-222-3850;
s Research Society International. Pis considered an important therapeutic option to slow or halt OA
progression.
OA has a strong genetic component5, however numerous
studies have failed to identify genes that provide the full genetic
susceptibility to the disease. This could be due to low penetrance
polymorphisms in the population but, it is proposed this could, in
part, be accounted for by inheritance of epigenetic modiﬁcations;
though in mammals such transgenerational inheritance appears
limited6.
Initially deﬁned as non-genetic transgenerational inheritance,
today the deﬁnition of epigenetics is a stable change in gene
expression between cell divisions, and sometimes generations, that
involves no change in the underlying DNA sequence7. Epigenetic
mechanisms include DNA methylation, histone modiﬁcations, and
microRNAs (miRNAs). Collectively, these enable the cell to respond
quickly to environmental changes. Aberrant epigenetic modiﬁca-
tions are associated with a number of pathological conditions,
probably occurring as a result of environmental factors and
ageing8,9, which are major risk factors for OA, and may impact on
the disease via such epigenetic mechanisms.
DNA methylation
DNA methylation involves the addition of a methyl group to the
DNA, at CpG dinucleotides, to convert cytosine to 5-methylcytosine
(meC). CpG sequences are often clustered in ‘islands’ near the
promoters of around 30% of genes. Methylation of these islands
correlates with suppression of gene expression and an important
function of DNA methylation is the silencing of transposons10.ublished by Elsevier Ltd. All rights reserved.
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certain promoters become methylated during development and
tissue differentiation11. Regions of lower CpG density that reside
close to CpG islands are termed ‘shores’12. Most tissue-speciﬁc
methylation appears to occur at these shores and correlates with
transcriptional repression of the corresponding gene. Further
complexity is added by the ﬁnding that methylation within a gene
body is common in ubiquitously expressed genes probably to
prevent incorrect transcriptional initiation13 (Fig. 1). A number of
proteins (e.g., MECP2) bind speciﬁcally to methylated DNA and lead
to transcriptional silencing via the recruitment of transcriptional
co-repressors and histone deacetylases (HDACs), thus remodelling
the local chromatin.
DNA methylation patterns are established and modiﬁed in
response to environmental factors by three DNA methyl-
transferases (DNMTs), DNMT1, DNMT3A and DNMT3B, the deletion
of any of which is essentially lethal in mice14,15. DNMT1 has
a preference for hemi-methylated DNA (one strand) and is there-
fore the maintenance DNMT, important for transferring patterns of
methylation to a newly synthesised strand after DNA replication.
DNMT3A and DNMT3B have been assigned as de novo DNA meth-
yltransferases16. In cartilage while DNMT3B expression is low,Fig. 1. DNA methylation and the regulation of gene expression. A: Under normal
circumstances, CpG islands located at the vicinity of gene promoter are hypomethy-
lated (open circles (B) above the DNA representation) permitting the binding of a TF
and transcription by the RNA polymerase (RNAP). An aberrant hypermethylation of the
CpG island (closed circles, C) favours the recruitment of a methyl-CpG-binding
domain containing protein (MBD) and subsequently, a DNMT close to the TSS (full
arrow), causing the transcriptional repression of the gene by precluding the possible
binding of a TF and/or the RNAP. B: Less CpG-dense ‘shores’ reside about 2 kb upstream
from the transcription initiation site of the gene and regulate transcription similarly to
CpG islands by CpG site methylation12. C: Conversely, gene body methylation is found
in normally expressed genes and is able to prevent spurious initiation of transcription
from the gene body. These tend to be demethylated in disease allowing aberrant
transcription initiation (solid arrow) to occur.DNMT1 and DNMT3A are robustly expressed suggesting that these
enzymes contribute to the DNA methylation pattern of chon-
drocytes17. DNMT activity requires the presence of the methyl
donor S-adenosylmethionine (SAMe), a food supplement taken by
some OA patients which, in contrast to animal studies18, has shown
no efﬁcacy in clinical trials19,20.
The mechanism of demethylation in mammals is unclear,
although data suggests DNMT3A and DNMT3B may also act as
demethylases21. Two waves of demethylation, or reprogramming,
occur in mammals; in primordial germ cells (PGCs) and the early
embryo. In PGCs, although this demethylation is almost global,
around 7% of CpGs, which cluster in regions of recently acquired
retrotransposons, remain methylated. Thus, in mammals there is
little evidence for epigenetic transgenerational inheritance, in
contrast to plants where this is common6. The demethylation that
does occur in PGCs is partly an active process mediated by the
cytosine deaminase AID (or AICDA, activation-induced cytidine
deaminase) and the base excision repair pathway22.
Recently a new epigenetic mark, hydroxy-methylcytosine
(hmeC), has been identiﬁed23 whose function remains to be eluci-
dated but is potentially important in gene regulation and deme-
thylation24. Also, new data suggest that unmethylated CpG islands
are themselves platforms for gene regulation, being bound exclu-
sively by the CXXC ﬁnger protein 1 (Cfp1) to regulate the local
chromatin state25. Together these data add further complexity to
epigenetically regulated loci.
DNA methylation in cartilage and OA
No detailed global methylation analysis in OA has been per-
formed but analysis of the total DNAmethylation content in control
relative to OA cartilage by chromatography showed no differences17.
However, the examination of individual gene promoters in cartilage
and/or in chondrocytes suggests that a ﬁne regulation of DNA
methylation, implicating a few but strategically important CpG loci,
can have a large impact on gene expression and hence disease.
An early study using chick embryos reported the possible role of
DNA methylation in the regulation of type-I and II collagen genes
during chondrocyte differentiation and dedifferentiation26. More
recently, the promoters of COL2A1 and ACAN were found to be
hypomethylated in both normal and OA chondrocytes, thus not
correlating with the dramatic alteration in their expression during
the disease27,28. Similarly, the promoters of the transcription factors
(TFs) SOX9 and RUNX2 show a hypomethylated proﬁle independent
of their expression status during in vitro chondrogenesis29.
However, two CpG sites within the COL10A1 promoter appear to be
demethylated during chondrocyte differentiation from mesen-
chymal stem cells (MSCs) correlating with COL10A1 expression28.
GDF5, a factor involved in synovial joint development, mainte-
nance and repair is also genetically associated with OA suscepti-
bility via a C/T single nucleotide polymorphism (SNP) located
within its 50untranslated region (UTR)30. There is a signiﬁcant
reduction in the expression of the disease-associated T allele rela-
tive to the C allele, an effect termed differential allelic expression
(DAE) imbalance. Recent work suggests the C allele, which forms
a CpG dinucleotide, can be methylated in joint tissues, affecting
GDF5 expression and DAE; leading to the suggestion that ‘epige-
netics’ could further inﬂuence the penetrance of this allele in the
susceptibility to common musculoskeletal diseases31.
Metalloproteinase expression in normal cartilage is relatively
low but elevated in OA32 resulting in ECM degradation. A number of
metalloproteinase promoters show decreasedmethylation at single
CpG loci in OA cartilage compared to normal, which could underlie
the disease-associated change in expression; these include MMP3
[635, relative to the transcription start site (TSS)], MMP9 (36),
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sequences remains to be elucidated but the DNA binding abilities of
several TFs (e.g., AP-234) are methylation-sensitive leading to the
epigenetic regulation of the corresponding gene (e.g., Ref.35).
A region of the IL1B promoter is demethylated in human artic-
ular chondrocytes correlating with an increase in IL1B expression36.
LEP (leptin) expression is regulated via DNA methylation by OA
chondrocytes and interestingly, leptin down-regulation by RNA
interference (RNAi), decreases MMP13 expression37. Table I
provides a summary of the individual genes analysed in
chondrocytes.
Together, the studies of DNA methylation in OA provide
evidence that such mechanisms regulate metalloproteinase
expression either directly or indirectly. As DNA methylation is
a reversible process, a better understanding of the mechanisms
involved represents an alternative approach to develop new OA
therapeutic strategies.
Chromatin modiﬁcations
Closely linked with DNA methylation, gene expression is also
regulated by the packaging of eukaryotic DNA into nucleosomes.
Nucleosomes are considered repressive to transcription, but
through the enzymatic post-translational modiﬁcation of histones
by such modiﬁcations as acetylation, phosphorylation, methylation
and ubiquitination, this inhibition can be regulated38. The partic-
ular pattern of modiﬁcations present may ‘code’ for the factors
recruited and the transcriptional state of the underlying gene39.
Acetylation is mediated by histone acetyltransferases (HATs)
and occurs on speciﬁc lysine residues on the N-terminal tails of
histones, loosening the histone:DNA structure and allowing access
of the transcriptional machinery40. Deacetylases, which fall into
two types, classical HDACs that use a zinc-catalysed mechanism of
deacetylation41, and the sirtuin deacetylases that require NADþ42,
remove these acetyl groups resulting in hypo-acetylation.Table I
Summary of current cartilage genes screened for regulation by DNA methylation
Function Gene symbol Context Expression
level
Meth
ECM components COL1A* Differentiation [ Hypo
COL2A1* Differentiation e Hypo
COL2A1 OA, chondrogenesis e Hypo
COL10A1 Chondrogenesis [ Hype
ACAN OA e Hypo
MATN4 Chondrogenesis [ Hype
CHAD Chondrogenesis [ Hypo
Matrix-degrading enzymes MMP3 OA [ Hypo
MMP9 OA [ Hypo
MMP13 OA [ Hypo
ADAMTS4 OA [ Hype
Signalling IL1B OA [ Hype
SOCS2 OA e Hype
GREM1 Chondrogenesis e Hypo
SDF1 Chondrogenesis e Hype
BMP7 OA, ageing e NS, IN
GDF5 Chondrogenesis, OA e Hypo
TFs SOX9 Chondrogenesis [ Hypo
RUNX2 Chondrogenesis þ Hypo
SOX4 Chondrogenesis e Hypo
Others SOD2 OA e Hypo
LEP OA [ Hype
p21WAF1/CIP1 OA, ageing e Hypo
CHM1 Chondrogenesis [ Hypo
FGFR3 Chondrogenesis [ Hypo
GPR39 Chondrogenesis e Hypo
Genes are classiﬁed according to their function/role during physiological and pathophy
hypo, hypomethylation; UN, unchanged; DIFF, differential; DEC, decreased; NS, not spec
* Refers to chick.Numerous transcriptional activators or repressors have (or
recruit) HAT or HDAC activity, respectively. Many small molecule
histone deacetylase inhibitors (HDACi) have been developed, with
some undergoing clinical trials for various cancers43. HDACi also
show promise in rheumatoid arthritis (RA) models (see below).
Non-histone acetylated proteins have been identiﬁed, including
numerous TFs and signalling pathway proteins44, which has led to
the postulation that acetylation is as important a post-translational
regulatory mechanism as phosphorylation.
Histonemethylation is important for the formation of active and
inactive genomic regions and is associated with both transcrip-
tional activation and silencing45. Methylation of histone tails on
lysine or arginine residues is catalysed by histone methyl trans-
ferases (HMTs) and protein arginine methyltransferases (PRMTs)
which can add one ormoremethyl groups to regulate transcription.
These modiﬁcations are reversible via the action of histone
demethylases46.
Although overall histone modiﬁcations are more dynamic than
DNA methylation, some speciﬁc histone methylation modiﬁcations
are thought to be actively maintained during DNA replication,
therefore truly epigenetic47.
Histones, HDACs and arthritis
The OA ﬁeld has yet to beneﬁt from large scale analysis of
chondrocyte histone modiﬁcations. However, unlike the changes in
conditions such as cancer where global alterations in histone
modiﬁcations are found, such differences in OAmay be more subtle
and gene speciﬁc.
Most work in the OA ﬁeld has made use of HDACi to infer the
role of deacetylases in chondrocytes. HDACi can block cytokine-
induced proteoglycan release and cartilage resorption in explant
models indicating that HDAC activity is critical for the catabolic
activity of chondrocytes48,49, indeed HDACi repress cytokine-
induction metalloproteinases in chondrocytes49,50, howeverylation status Differential mCpGs Correlation Refs
, UN None  26
, UN None  26
, UN None  28
r, DIFF (1680, 1674) in MSCs þ 28
, UN None  27
r, UN None  29
, UN None  29
, DIFF 635 þ 33
, DIFF 36 þ 33
, DIFF 110 þ 33, 107
r, DIFF 753 þ 33
r, DIFF (256, 299) þ 36
r and hypo, UN None  108
, UN None  29
r, DEC Not mentioned þ 29
C Not mentioned þ 109
(1305, 1300, 338, 323, 312, 221) þ 31
, UN None  29
, UN None  29
, UN None  29
, DIFF (222, 183,  154) þ 110
r, DEC Not mentioned þ 37
, UN None  17
, UN None  29
, UN None  29
, UN None  29
siological conditions. The methylation status is listed as: hyper, hypermethylation;
iﬁed; INC, increased.
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and MMP13 following interleukin(IL)-1 stimulation51, suggesting
repression by histone-independent mechanisms. Certainly, many
signalling pathway proteins are subject to reversible acetylation44,
however in chondrocytes HDACi do not appear to modulate NF-kB
signalling48.
HDACi also modulate the expression of ECM components,
although the duration of administration appears important, for
example, short-term treatment of chondrocytes (<24 h) induces
anabolic cartilage gene expression such as COL2A1, COL9A1, COMP,
andACAN52,53,while extended treatment repressesmanyof the same
transcripts50,53,54. The early positive effects may be a direct result of
HDAC inhibition since HDAC1 and HDAC2 overexpression represses
ACAN and COL2A153, whereas the long-term inhibitionmay be due to
the up-regulation of repressive factors such as Wnt-5A54 or NAB155.
In vivo, the only assessment of the role of HDACs in OA was in
a rabbit anterior cruciate ligament transaction (ACLT) model, where
animals given a weekly injection of HDACi developed signiﬁcantly
less cartilage erosion, concomitant with reduced expression of
collagenases and IL156. Several studies have shown that HDACi canFig. 2. Histone modiﬁcations and the regulation of gene expression. A: All histones are subj
and 2B are particularly subject to ubiquitination. The main families of enzymes catalysing the
modiﬁcations are found associated with active and inactive chromatin regions. Active region
arrow). High levels of tri-methylated H3K4, H3K79 and H3K36 are also found, particularly aro
of active gene expression are also present. By contrast, inactive regions exhibit low levels ofexhibit beneﬁcial effects on animal models of RA, mainly by sup-
pressing synovitis and reducing the levels of inﬂammatory cyto-
kines (e.g., Ref. 57).
In human disease, HDAC7 was reported to be differentially
expressed between OA and normal cartilage, where its depletion
controlled MMP13 expression58. HDAC1 and HDAC2 are reportedly
up-regulated in OA chondrocytes53, although overall HDAC activity
is similar between OA and normal synovial tissue59. HDAC activity
decreases during human articular chondrocyte dedifferentiation,
correlating with a reduction in COL2A1 expression, and HDACi
prevent the redifferentiation of dedifferentiated chondrocytes,
suggesting that HDAC activity is crucial for the maintenance of the
chondrocyte phenotype54.
In terms of histone methylation in chondrocytes, IL1 induces
histone H3K4 di- and tri-methylation around the COX2 and iNOS
promoters, but not MMP13, which correlated with the recruitment
of SET-1A, a methyltransferase with increased expression in OA
compared with normal tissue. Histonemethyltransferase inhibition
or depletion of SET-1A prevented IL1 induction of COX2 and iNOS60
(Fig. 2).ect to modiﬁcations such as acetylation, methylation and phosphorylation; histones 2A
addition or removal of these modiﬁcations are listed. B: Gene expression. A number of
s exhibit high levels of histone acetylation especially around the promoter and TSS (full
und the indicated regions of the transcribed gene. Other listed modiﬁcations indicative
histone acetylation and high levels of H3K9, H3K27 and H4K20 di- and tri-methylation.
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In cartilage, the sirtuin SirT1 is essential for chondrocyte
survival by enhancing insulin-like growth factor signalling to
inactivate p53 and prevent apoptosis61. SirT1 levels decrease in
dedifferentiating chondrocytes, in OA cartilage and in cartilage
exhibiting OA-like damage, which could account for the loss of
chondrocytes in OA61e64. The inhibition of SirT1 leads to an increase
in chondrocyte apoptosis while addition of resveratrol, a sirtuin
activator, protects chondrocytes from cell death64. Exposure of
chondrocytes to ionising radiation signiﬁcantly increases the
number of senescent cells by reducing SirT1 levels, since this can be
blocked by SirT1 overexpression or resveratrol65. Interestingly, the
function of SirT1 is closely linked to hypoxia where, via redox-
sensing, it can directly deacetylate and thus activate HIF-2a66,
resulting in the up-regulation of metalloproteinases and cartilage
destruction67.
Aside from its role in survival, SirT1 also promotes cartilage
matrix gene expression such as ACAN, COL2A1, COL9A1 and COMP,
potentially via the deacetylation of SOX962, while also inhibiting
ADAMTS5 expression63. SirT1 also plays a role in skeletal homeo-
stasis and osteoporosis since haplo-insufﬁcient female mice exhibit
a signiﬁcant reduction in bone mass characterised by decreased
bone formation and increased marrow adipogenesis68. The role for
SirT1 in muscle physiology and disease has also been extensively
studied69.
miRNAs
Small non-coding RNAs known as miRNAs are important
regulators of gene expression inmetazoan genomes. They are short,
20- to 23-nucleotide-long single-stranded non-coding RNAs, tran-
scribed from either intergenic regions with their own promoter or
as part of a gene where they are usually intronic. Following pro-
cessing to short stem-loop structures, pre-miRNA, they are expor-
ted from the nucleus. The cytoplasmic RNase III enzyme Dicer
removes the stem-loop forming a miRNA duplex consisting of two
arms of the loop (often named -5p and -3p respectively). One
miRNA of the duplex is then integrated into the RNA-induced
silencing complex (RISC), where it base pairs, via nucleotides 2e8
of the miRNA ‘seed-sequence’, with generally the 30UTR of targetTable II
miRNAs targeting OA and cartilage-speciﬁc processes
miR Target Species Effect Validation
140 Hdac4 M. musculus Y þ on 30UT
Cxcl12 M. musculus Y þ and  o
IGFBP5 H. sapiens Y þ and  o
Smad3 M. musculus Y þ and  o
ADAMTS5 H. sapiens Y þ on mRN
M. musculus Y Gain and
30UTR luc
Dnpep M. musculus Y anti-Ago
30UTR luc
22 BMP7 H. sapiens Y þ and  i
PPARa Y þ and  o
27b MMP13 H. sapiens Y þ and  o
675 COL2A1 (indirect) H. sapiens [ þ and  o
34 COL2A1 (IL1-induced) H. sapiens Y  on mRN
iNOS (IL1-induced)
18a CCN2 H. sapiens Y þ on part
145 SOX9 H. sapiens Y þ on 30UT
M. musculus Y þ and  o
365 HDAC4 G. gallus Y þ on 30UT
455-3p ACVR2B H. sapiens Y þ on 30UT
SMAD2 þ on 30UT
CHRDL1 þ on 30UT
þ, overexpression; , inhibition; WB, western blot. Mus musculus (M. musculus), Homo smRNAs70. Depending on the level of complementarity between
miRNA and target mRNA, RISC either cleaves or suppresses trans-
lation of the mRNA, the latter being predominant, but still some-
what controversial, in mammals71.
miRNAs were originally mooted as ‘ﬁne tuning’ gene expression.
Recently, particularly through the generation of knockout and
transgenic mice for speciﬁc miRNAs, it has become clear that they
can be major regulators in development and play a signiﬁcant role
in various pathologies.
miRNAs and chondrocytes
Loss of the miRNA processing enzyme Dicer in mice leads to
embryonic day 7.5 lethality. However using conditional Dicer-null
mice, an overall role for miRNAs in limb mesenchyme72 and skel-
etogenesis73 has been demonstrated. In terms of skeletogenesis,
the severe growth defects observed in these mice are caused by
a decrease in proliferating chondrocytes in the growth plate and
amore rapid onset of hypertrophy73. Table II provides a summary of
the role of miRNAs in OA and cartilage.
miR-140
Cartilage miRNA research to date has focussed largely on
miR-140 which was originally identiﬁed as a cartilage-restricted
miRNA in developing zebraﬁsh74. Similarly, during murine skel-
etal development miR-140 is speciﬁcally expressed in cartilage
tissues75. In humans, the expression of miR-140 increases during
chondrogenesis and is more abundant in articular cartilage, but
reduced in OA76e78. In vitro murine targets of miR-140 include
Hdac475, a repressor of Runx2 and MEF2C79,80, Cxcl12 (SDF-1)81 and
Smad382, while in humans miR-140 decreases ADAMTS5 and
IGFBP5, and increases ACAN expression76,77.
miR-140-null mice are born normally but within 4 weeks have
impaired growth, due to shorter long bones, and exhibit cranio-
facial deformities83. The articular joint cartilage initially appears
normal, but the mice show an early onset OA-like disease and
greater susceptibility to surgically-induced OA. Conversely, in an
antigen-induced arthritis model, transgenic overexpression of
miR-140 protected against cartilage damage. Although also a target
in mice, the inhibition of Adamts5 by miR-140 is only modestFunction Refs
R luciferase and WB Protein deacetylation 75
n 30UTR luciferase and mRNA Signalling 81
n mRNA Signalling 76
n 30UTR luciferase and WB Signalling 82
A Matrix-degrading enzyme 77
loss of function on mRNA, IHC and
iferase
83
RNA immunoprecipitation, þ on
iferase and WB
Signalling 84
nhibition on WB 78
n WB Signalling
n 30UTR luciferase and ELISA Matrix-degrading enzyme 94
n mRNA and WB ECM component 95
A and IHC ECM component 96
Signalling
ial 30UTR luciferase and ELISA Signalling 111
R luciferase and WB Transcription 98, 99
n 30UTR luciferase and WB
R luciferase, þ and  on WB Protein deacetylation 97
R luciferase Signalling 100
R luciferase Signalling
R luciferase Signalling
apiens (H. sapiens), Gallus gallus (G. gallus)
Fig. 3. miRNAs in the regulation of skeletogenesis and OA. Long bones are formed by
the highly regulated process of endochondral ossiﬁcation in which chondrocytes
undergo proliferation and hypertrophy with the cartilaginous matrix ﬁnally replaced
by bone. Dicer-null mice show an overt developmental skeletal phenotype, pointing to
an important role of miRNAs in skeletogenesis73. This is emphasised by two miR-140-
null mice which show a modest skeletal phenotype83,84. SOX9 regulates the expression
of miR-14077 whose targets include DNPEP84 (and subsequently BMP (bone morpho-
genetic protein) signalling) and HDAC475 (which regulates MEF2C80 and RUNX279).
HDAC4 is also targeted by miR-365, a miRNA induced by the cyclical loading of
chondrocytes97. SOX9 is also directly repressed by miR-14598,99. All these genes have
important roles in skeletogenesis. The epiphyses of endochondral bones are sur-
rounded by a layer of articular hyaline cartilage which is lost, probably via the action of
aggrecanases and collagenases (e.g., ADAMTS5 and MMP13 respectively), in OA. miR-
140 appears to directly target ADAMTS5, but can also regulate IL1 signalling, as does
miR-146a92, to modulate MMP13 levels. MMP13 is also a direct target of miR-2776,94.
Type-II collagen is a major component of hyaline cartilage and appears to be regulated
by the hypoxia induced miR-67595.
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this end, a second miR-140-null mouse with a skeletal phenotype
was recently reported and the authors show that miR-140 targets
Dnpep (aspartyl aminopeptidase), which may antagonise BMP
signalling84.
miR-140 resideswithin an intronofWWP2, an E3 ubiquitin ligase
recently shown to have an important role in cartilage biology via its
mono-ubiquitination of TF Goosecoid85. In addition, miR-140
regulates PDGF (platelet-derived growth factor) signalling and
impinges on palatogenesis86, a process for which WWP2 is essen-
tial87. The chondrocyte TF SOX9 directly promotes the expression of
WWP2 and miR-14087,88. IL1 and transforming growth factor
(TGF)-b also regulate miR-140 levels77,82 but this could be indirect
since these factors also regulate SOX9 expression (Fig. 3).Other miRNAs
The role of other miRNAs in OA is as yet unclear. Two screens of
miRNA expression in normal comparedwith OA cartilage have been
published78,89. Firstly, Jones et al. highlighted the altered expression
of miR-9, miR-98 and miR-146 in OA cartilage and showed that
their overexpression reduced IL1-induced TNFa production, whilst
inhibition or overexpression of miR-9 modulated MMP13 secre-
tion89. Secondly, Iliopoulos et al. identiﬁed several miRNAs altered
in OA cartilage78. They focused on miRNAs whose expression
correlated with body mass index and demonstrated that miR-22
targets PPARa and BMP7 with indirect effects on IL1, MMP13 andACAN expression. Consistent with the ﬁndings of Jones et al.,
Yamasaki et al. found that the expression of miR-146a decreases
with increased OA severity90. IL1 stimulation induces miR-146a
expression in chondrocytes, which via a feedback loop, represses
IL1-induced gene expression91, consistent with its role in the
30UTR-mediated repression of IRAK1 and TRAF6 to suppress TLR
(toll-like receptor) signalling92. Recently, miR-146a has also been
linked to the pain-related pathophysiology of OA93.
In contrast, IL1 stimulation represses miR-27b expression in
chondrocytes. miR-27b expression is reduced in OA cartilage where
it inversely correlates with MMP13, which it directly targets94.
Dudek et al. identiﬁed H19, a non-coding RNA, processed to form
miR-675, as tightly regulated by SOX9 during chondrocyte differ-
entiation. miR-675 upregulates COL2A1 expression, albeit indi-
rectly95. In rat chondrocytes IL1 induces miR-34, which appears to
counteract the effect of IL1 on Col2a1 and Nos2 (iNOS) expression96.
Stimulation of chondrocytes by cyclical loading regulates the
expression of a number of miRNA including miR-365 which, like
miR-140, directly targets the expression of HDAC497.
Screens in dedifferentiating articular chondrocytes, bovine carti-
lage, chondrosarcoma and osteochondroma have establishedmiRNA
proﬁles for which further studies are required to identify targets in
cartilage. Recent work based upon such screens has identiﬁed miR-
145 and miR-455-3p as miRNAs that warrant further investigation
in chondrogenesis and OA. miR-145 directly targets SOX9 to control
chondrogenesis98,99 while miR-455-3p appears to regulate TGFb
signalling by suppressing the Smad2/3 pathway100 (Fig. 3).
miRNAs are also found in plasma and may even be able to enter
recipient cells, opening up the possibility of exogenous regulation
of gene expression101. Murata et al. examined the potential of
miRNA as diagnostic biomarkers from OA patients and found
a number of miRNAs in plasma some of which were found at
different levels between RA and OA patients102.
Epigenetic analysis
Epigenetics methodologies have until recently been small-scale,
low throughput focussing on the analysis of a single gene, many
using polymerase chain reaction (PCR) as the ﬁnal (or penultimate)
analytical or quantitative based step. However, many of these
techniques now employ tiling genome array-hybridisation tech-
nology or high-throughput DNA sequencing as their ﬁnal read-outs
to make whole epigenome analysis a reality.
Analysis of DNA methylation
After isolation of genomic DNA, methylation analysis can have
a number of initial steps. Many original techniques used
methylation-sensitive and insensitive restriction endonucleases
followed by either PCR or gel-based methods to compare the DNA
fragments generated after digestion. Newer techniques use an
initial afﬁnity enrichment step, either an antibody against meC
(or more recently hmeC) or an antibody against, or a tagged, methyl-
binding protein (e.g., MBD2). After meC DNA enrichment PCR, tiling
arrays or high-throughput DNA-sequencing methods can be
employed103. The most frequently used method for DNA methyla-
tion analysis is that of bisulphite conversion, which leads to the
deamination of unmethylated cytosine residues in preference to
those methylated. The deaminated cytosines are converted to
thymidines (via uracil) turning an epigenetic into a genetic differ-
ence. This DNA is then subjected to PCR using bisulphite speciﬁc
PCR primers. The amount of methylation in the amplicon can then
be determined by either direct pyrosequencing, mass spectrometric
analysis (Sequenom EpiTyper) or cloning and Sanger sequencing.
Bisulphite converted DNA can also be subjected to array-based
M.J. Barter et al. / Osteoarthritis and Cartilage 20 (2012) 339e349 345analysis or perhaps the most comprehensive technique available,
whole genome shotgun bisulphite sequencing (WGSBS). It is worth
noting that no technique is perfect or totally comprehensive in
terms of analysing all possible CpGs. Restriction enzyme techniques
are limited by the number of different restriction enzymes avail-
able, afﬁnity puriﬁcation biases towards CpG-dense genomic
regions, and with WGSBS around 10% of all CpGs will not be able to
be aligned successfully to the genome. WGSBS, like all high-
throughput sequencing is currently expensive and has bio-
informatic, data management and storage issues.
Analysis of chromatin modiﬁcations
Chromatin immunoprecipitation (ChIP) experiments revolu-
tionised the study of chromatinmodiﬁcations in part because of the
advent of reliable anti-chromatin antibodies. ChIP experiments
initially employed PCR, and now real-time PCR as a ﬁnal readout.
However, ChIP followed by hybridisation to genomic tiling arrays or
now ChIP-seq experiments are increasingly common. As with
WGSBS, the amount of data generated makes analysis and inter-
pretation of such experiments problematic104.
miRNA analysis
miRNA analysis is two-fold, ﬁrstly miRNA identiﬁcation and
expression and secondly target identiﬁcation and analysis. A number
of platforms for miRNA expression are available including arrays and
PCR proﬁling. More recently, high-throughput sequencing can be
used to both quantify and identify novel miRNAs. Initially expensive,
such techniques are becoming more affordable due to both newer
instruments and the ability to multiplex reactions, however such
techniques are not without problems including sequence bias105.
In terms of target identiﬁcation, a number of prediction pro-
grammes exist which use slightly different algorithms to identify
targets, all with fairly limited success. Experimental techniques to
identify targets include microarray analysis following miRNA
knock-down or overexpression or quantitative proteomic methods.
Again, as with ChIP and methylation analysis, new methods for
miRNA target identiﬁcation involve high-throughput sequencing
following some form of enrichment, normally immunoprecipita-
tion of the Ago component of the RISC complex. Perhaps the most
important recent development is the Ago HITS-CLIP method which
uses UV cross-linking to allow the precipitation of miRNAs with
their target mRNAs106.
Once identiﬁed, targets are normally validated by cloning of the
30UTR downstream of a reporter gene followed by transfectionwith
the appropriate miRNA. The generation of such constructs can be
time-consuming thus 30UTR libraries are now commercially
available.
Conclusions and perspectives
Research into the epigenetics of OA is still in its infancy but
current data suggests that the various mechanisms will play a role
in the pathophysiology of the disease and may well lead to new
research avenues or even therapeutics. Of course, the same difﬁcult
questions arise in epigenetic analysis of OA as with any OA
research: should cartilage be the focus? Should comparisons be
between young vs old, ‘normal’ vs OA tissue?
ThemiRNA ﬁeld has advanced the most in OA, probably because
miRNAs are essentially genes therefore tractable by standard
molecular techniques. Dicer-null mice demonstrate the importance
of miRNAs for long bone formation, while the deletion of a single
miRNA, miR-140, has a clear developmental phenotype with early-
onset OA. The severity difference between the Dicer and miR-140-null animals clearly indicates that further important miRNAs
remain to be identiﬁed. Conditional-null animals, including for
miR-140, still need to be generated in order to distinguish the role
of miRNAs in development and disease. Many other challenges also
remain, especially in terms of miRNA target identiﬁcation; such
targets are likely to identify new pathways involved in OA. Thera-
peutically, inhibitors of speciﬁc miRNAs, modiﬁed locked-nucleic
acids, are already undergoing evaluation and could be explored in
OA.
To date, there have been no global chromatin or DNA methyla-
tion analyses in OA. A number of chromatin modifying enzymes
certainly have important roles in skeletogenesis, such as HDAC479,
and will undoubtedly in OA. Small molecule inhibition of these
enzymes is an intriguing therapeutic option and at least for HDACi
has shown efﬁcacy in small animal arthritis models including OA56.
However, current HDACi target multiple family members and
although some HDAC speciﬁc inhibitors exist the appropriate
HDACs to target in OA remain to be identiﬁed. Candidate gene
approaches have led to some interesting observations with regards
promoter methylation which suggests that global epigenetic anal-
ysis would be valuable. Many of the technical and data related
issues with global epigenetic analysis will clearly be resolved, and it
is likely that soon the ultimate in epigenetic analysis, whole
genome single cell analysis, will be possible. However, signiﬁcant
hurdles remain, in particular how to distinguish between cause and
effect for speciﬁc epigenetic modiﬁcations or patterns on gene
expression changes, and the major question, if epigenetic changes
that lead to OA are identiﬁed, how could this be therapeutically
targeted to slow or prevent disease?Contributions
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